CCBIO Seminar – Jean Paul Thiery
Speaker: Jean Paul Thiery, Bioland Laboratory, Guangzhou Regenerative Medicine and Health, People’s Republic of China, and CCBIO, University of Bergen, Norway. Due to the Covid-19 circumstances, the seminar will be held through a digital platform (Zoom Webinar), so you can attend even from the comfort of your own home.
Speaker: Jean Paul Thiery, Bioland Laboratory, Guangzhou Regenerative Medicine and Health, People’s Republic of China, and CCBIO, University of Bergen, Norway
Title: "Epithelial mesenchymal transition in carcinoma; therapeutic intervention"
Place: digital event as webinar in Zoom. Access codes will be available here a couple of days before the event.
Time: December 17, 2020 at 14:30
Chair: Agnete Engelsen
Short bio: Jean Paul Thiery is a senior scientist at the Bioland Laboratory, Guangzhou, China and an affiliated professor at CCBIO, the University of Bergen, Norway. His influential works include pioneering studies in cell adhesion and migration in early embryogenesis and in elucidating the roles of growth factors and adhesion signaling molecules in Epithelial-Mesenchymal Transitions (EMT). Jean Paul Thiery is credited to be the first to propose that EMT controls carcinoma cell invasion and dissemination. Currently, his research focuses on oncogenomics and the creation of functional approaches to characterize bladder and lung carcinoma progression with the goal to apply EMT-based therapeutic approaches.
Abstract: We previously proposed that Epithelial-Mesenchymal Transition (EMT), a developmental mechanism, becomes high-jacked by carcinoma cells for their invasion and metastasis and have established an EMT scoring system applicable to all carcinoma. In this presentation, I will briefly discus when and how an EMT phenotype can be acquired in the primary tumors or in CTCs. I will then describe our strategy to harness the EMT concept as a complementary strategy to currently available targeted therapeutics. I shall present the potential to treat mesenchymal-like tumors in bladder carcinoma based on our analysis of the mechanisms driving EMT in this tumor type. I will also show that we can potentially improve immunotherapy-based treatment by interfering with the EMT phenotype.